BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
344.58
+0.11 (+0.03%)
At close: 4:00PM EDT

342.20 -2.38 (-0.69%)
After hours: 6:01PM EDT

Stock chart is not supported by your current browser
Previous Close344.47
Open346.56
Bid290.00 x 100
Ask349.90 x 100
Day's Range343.54 - 348.84
52 Week Range244.28 - 348.84
Volume1,247,013
Avg. Volume1,265,795
Market Cap72.86B
Beta0.47
PE Ratio (TTM)22.61
EPS (TTM)15.24
Earnings DateOct 24, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est336.79
Trade prices are not sourced from all markets
  • Dow pierces 23,000 as earnings boost the blue chips higher
    Yahoo Financeyesterday

    Dow pierces 23,000 as earnings boost the blue chips higher

    The Dow (^DJI) pierces 23,000 after strong earnings beats by UnitedHealth (UNH) and Johnson & Johnson (JNJ), but quickly retreats and settles into a low volume trading range for the balance of the day. Plus, Gary Cohn speaks to Yahoo Finance in Washington, D.C. The president’s chief economist tells us what’s open for negotiation and what’s not. Plus, our prophecy for posterity — or as we usually call it, the look ahead — for everything you need to know about tomorrow with your favorite interlocutor. Catch The Final Round at 3:55 p.m. with Jen Rogers and Yahoo Finance’s Myles Udland and Dan Roberts.

  • Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?
    Zacks12 hours ago

    Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?

    At Biogen's (BIIB) Q3 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in the same quarter.

  • Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug
    Zacks14 hours ago

    Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug

    Key highlights include regulatory updates from Exelixis (EXEL) and Spark Therapeutics and pipeline updates from Regeneron and Ionis among others.

  • Business Wire14 hours ago

    Biogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive Approach

    Biogen confirms its comprehensive approach to tackle multiple sclerosis at the seventh Joint Meeting of the European Committee for Treatment and Research in MS and Americas Committee for Treatment and Research in MS .

  • MarketWatch14 hours ago

    Biogen’s stock gets a big boost from 2 upgrades a week before earnings

    Biogen’s stock rallies to 2-year high after two analysts raise their ratings to buy and their price targets to at least $400.

  • Where to Find Value in Healthcare Stocks
    Zacksyesterday

    Where to Find Value in Healthcare Stocks

    The Biotech stocks have been on a big run in 2017, but that doesn't mean there aren't some healthcare values still out there.

  • Biogen Biomarkers Mark Way To Alzheimer's, Parkinson's Treatments
    Investor's Business Dailyyesterday

    Biogen Biomarkers Mark Way To Alzheimer's, Parkinson's Treatments

    Biogen eyes therapies for Parkinson's, Alzheimer's and more using biomarkers, biological mechanisms and other cutting-edge technologies.

  • 3 Drug Stocks Hitting 52-Week Highs: Are They Buys?
    Motley Fool2 days ago

    3 Drug Stocks Hitting 52-Week Highs: Are They Buys?

    2017 has been a great year for these drug stocks. But will their momentum taper off?

  • Barrons.com2 days ago

    [$$] More Biotechs That Can Beat Q3 Views

    Credit Suisse Overall, we think most U.S. biotech companies look to be in-line-to-above consensus estimates. Where we have conviction and are focused into quarter: We think Biogen (BIIB) has potential to beat based mostly on Spinraza U.S. trends after reviewing a recent slide deck from the CureSMA website.

  • 6 Top Biotech Companies In Innovation Earn Recognition In New Awards
    Investor's Business Daily3 days ago

    6 Top Biotech Companies In Innovation Earn Recognition In New Awards

    Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?

  • This No. 1-Ranked Medical Stock Is Breaking Out With Q3 Earnings Due
    Investor's Business Daily5 days ago

    This No. 1-Ranked Medical Stock Is Breaking Out With Q3 Earnings Due

    Clinical research firm PRA Health Sciences is testing a new breakout move.

  • Barrons.com5 days ago

    Can Biotech Stay Healthy Through the End of 2017?

    Credit Suisse's Alethia Young and her team take a look at the biotech sector ahead of earnings, writing that they expect large-cap companies' strength to continue through the end of the year. Young writes that she expects most companies to be either in-line or above consensus estimates when they report third-quarter results, as large cap biotechs have been strong heading into t he third quarter. Among stocks where she has the most conviction in the quarter, she thinks that Biogen (BIIB) can beat expectations thanks to Spinraza (it's spinal muscular atrophy drug) trends in the U.S. She writes that she thinks investors should expect a "solid" quarter from Bioverativ (BIVV) as well, and will also be  focusing on sales from Regeneron's (REGN) Dupixent and Gilead's (GILD) HCV franchise.

  • Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit
    Zacks8 days ago

    Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit

    With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.

  • 5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings
    Zacks8 days ago

    5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings

    Here is a look at 5 pharma and biotech stocks including Pfizer (PFE) that are expected to post a positive earnings surprise in Q3.